Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
Journal
JAMA oncology
Journal Volume
9
Journal Issue
9
Date Issued
2023-09-01
Author(s)
Mazieres, Julien
Paik, Paul K
Garassino, Marina C
Le, Xiuning
Sakai, Hiroshi
Veillon, Remi
Smit, Egbert F
Cortot, Alexis B
Raskin, Jo
Viteri, Santiago
Wu, Yi-Long
Ahn, Myung-Ju
Ma, Rui
Zhao, Jun
O'Brate, Aurora
Berghoff, Karin
Bruns, Rolf
Otto, Gordon
Johne, Andreas
Felip, Enriqueta
Thomas, Michael
Abstract
MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 (METex14)-skipping non-small cell lung cancer (NSCLC); however, data with longer follow-up and in larger populations are needed to further optimize therapeutic approaches.
SDGs
Type
journal article